The Global Influenza Market

Table of Contents

Chapter- 1: INTRODUCTION -- Complimentary 3

• STUDY GOALS AND OBJECTIVES 1
• REASONS FOR DOING THE STUDY 1
• SCOPE OF REPORT 1
• METHODOLOGY 2
• RELATED BCC STUDIES 2
• ANALYST CREDENTIALS 3
• BCC ONLINE SERVICES 3
• DISCLAIMER 3

Chapter-2: SUMMARY 2

• THE INFLUENZA MARKET: MAJOR MARKETS SUMMARY 4
• SUMMARY TABLE GLOBAL INFLUENZA MARKET ANALYSIS BY PRODUCT SEGMENT, THROUGH 2014 ($ MILLIONS) 5
• SUMMARY FIGURE GLOBAL INFLUENZA MARKET ANALYSIS BY PRODUCT SEGMENT, 2007-2014 ($ MILLIONS) 5

Chapter-3: INDUSTRY OVERVIEW 17

• OVERVIEW 6
• HISTORY OF THE MARKET 6
• EPIDEMICS/PANDEMICS 6
• Spanish Influenza 1918 - 1919 6
• Asian Influenza 1957 7
• Hong Kong Influenza 1968 7
• Swine Flu 1976 7
• Russian Influenza 1977 7
• Avian Flu 1961, 1997, 2003 - 2009 (sporadic) 8
• Novel Influenza H1N1 2009 8
• VIRUS MUTATIONS 9
• TYPES OF INFLUENZA 9
• Influenza Type A 10
• Influenza A H5 10
• Influenza A H7 10
• Influenza A H9 10
• Influenza A H1 10
• Influenza Type B 11
• Influenza Type C 11
• WORLD ACTIVITY OF INFLUENZA VIRUSES 11
• TABLE 1 WORLDWIDE INFLUENZA ACTIVITY, COUNTRIES AFFECTED BY TYPE 11
• TABLE 1 (CONTINUED) 12
• THE WORLD HEALTH ORGANIZATION (WHO) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC): INFLUENZA RESPONSE 13
• WORLD HEALTH ORGANIZATION 13
• CENTERS FOR DISEASE CONTROL AND PREVENTION 13
• American Recovery and Reinvestment Act (ARRA) of 2009 14
• U.S. VIRAL SURVEILLANCE 14
• TABLE 2 VIRAL SURVEILLANCE, PERCENT OF INFLUENZA VIRUS TYPE, 2005 - 2009 FLU SEASONS 15
• VACCINE RECOMMENDATIONS 15
• TABLE 3 THIMEROSAL CONTENT OF INFLUENZA VACCINES 16
• TABLE 4 CDC INFLUENZA VACCINE RECOMMENDATIONS 17
• DEVELOPMENT OF FLU VACCINES 17
• TABLE 5 MIDAS RESEARCH TEAMS AND AREAS OF STUDY 18
• UNIVERSAL VACCINE 18
• WORLD DEMOGRAPHICS AND INFLUENZA INCIDENCE/MORTALITY 18
• TABLE 6 ESTIMATED WORLD POPULATION AND ANNUAL GROWTH, BY SELECTED AGE GROUP AND SELECTED YEARS THROUGH 2030 (# MILLIONS) 19
• FIGURE 1 ESTIMATED WORLD POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS 2000 - 2030 (# MILLIONS) 19
• TABLE 7 POPULATION BY SELECTED COUNTRIES, THROUGH 2014 (MILLIONS) 20
• FIGURE 2 POPULATION BY SELECTED COUNTRIES, 2007 - 2014 ($ MILLIONS) 21
• TABLE 8 WORLDWIDE INFLUENZA STATISTICS, ESTIMATED ON 2009 DATA AND POPULATION 21
• TABLE 9 UNITED STATES VIRAL STATISTICS, ESTIMATED ON 2009 DATA AND POPULATION 22

Chapter-4: ISSUES AFFECTING THE MARKET 23

• H1N1 OUTBREAK 2009 (SWINE FLU) 23
• DIAGNOSTICS 23
• AVIAN FLU 24
• U.S. GOVERNMENT INTERVENTION 24
• TABLE 10 COUNTRIES AFFECTED BY CURRENT CDC AND USDA BIRD IMPORT RESTRICTIONS 25
• AVIAN FLU SURVEILLANCE 26
• TABLE 11 WHO - REPORTED CASES OF AVIAN INFLUENZA A/(H5N1) IN HUMANS 26
• FIGURE 3 WHO - REPORTED CASES OF AVIAN INFLUENZA A/ (H5N1) IN HUMANS, 2003-2009 27
• THE WHO AND CONTAINMENT ISSUES FOR PANDEMIC INFLUENZA 27
• TABLE 12 APPROVED WHO INFLUENZA CENTERS BY REGION 28
• TABLE 12 (CONTINUED) 29
• TABLE 12 (CONTINUED) 30
• TABLE 12 (CONTINUED) 31
• TABLE 12 (CONTINUED) 32
• TABLE 12 (CONTINUED) 33
• TABLE 12 (CONTINUED) 34
• TABLE 13 CONFIRMED CASES OF AVIAN FLU OUTBREAKS IN ANIMALS WORLDWIDE, 2003-MAY 2009 (SUBTYPE H5N1 IN POULTRY) 35
• TABLE 13 (CONTINUED) 36
• FIGURE 4 CONFIRMED CASES OF AVIAN FLU OUTBREAKS IN ANIMALS WORLDWIDE (%) 36
• FIGURE 4 (CONTINUED) 37
• INTERNATIONAL INFLUENZA VACCINE STOCKPILE ORDERS 37
• PRE - PANDEMIC VACCINATION 37
• ANTIVIRAL RESISTANCE 38
• U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICE' S (HHS) CONTRACTS FOR INFLUENZA PREPAREDNESS 38
• TABLE 14 ORDERS OF BULK SUPPLY NOVEL H1N1 VACCINE ANTIGEN AND ADJUVANT, 2009 ($ MILLIONS) 39
• BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA) 39
• HHS CONTRACTS FOR RELATED TECHNOLOGIES 39
• PREVIOUS U.S. VACCINE CONTRACTS 40
• RECREATED VIRUSES 40
• IMMATERIALIZED MARKET RISK 41
• MEDIA COVERAGE AND VACCINATIONS 42
• EPIDEMIC/PANDEMIC THREAT 42
• TABLE 15 ESTIMATED INCIDENCE OF NOVEL H1N1 INFLUENZA FOR 2009 SECOND WAVE IN SEVERE OUTBREAKS BASED ON POPULATION ESTIMATES, U.S. CENSUS BUREAU INTERNATIONAL DATABASE SELECTED COUNTRIES (THOUSANDS) 43
• TABLE 15 (CONTINUED) 44
• WORLD INFLUENZA IMAPCT 45
• SEASONAL FLU ECONOMIC IMPACT IN THE U.S. 45
• HOSPITAL BED UTILIZATION DURING INFLUENZA PANDEMIC 45

Chapter-5: PATENT ANALYSIS 10

• OVERVIEW 46
• INFLUENZA PATENTS BY PATENT NUMBER 46
• TABLE 16 RECENT U.S. PATENTS FOR INFLUENZA TECHNOLOGY BY PATENT NUMBER 47
• TABLE 16 (CONTINUED) 48
• TABLE 16 (CONTINUED) 49
• TABLE 17 NUMBER OF U.S. PATENTS FOR INFLUENZA MARKET COMPETITOR 50
• FIGURE 5 NUMBER OF U.S. PATENTS FOR INFLUENZA MARKET COMPETITOR 51
• ABBOTT LABORATORIES 52
• AMGEN 52
• MEDIMMUNE/AVIRON 52
• BAXTER HEALTHCARE 53
• BIOTA SCIENTIFIC 53
• CONNAUGHT LABORATORIES, INC. 53
• CRUCELL HOLLAND B.V. 54
• GLAXOSMITHKLINE 54
• MERCK & CO. INC. 54
• NOVARTIS VACCINES/CHIRON 55
• PROTEIN SCIENCES CORP. 55
• YEDA RESEARCH AND DEVELOPMENT 55

Chapter-6: INFLUENZA THERAPIES/VACCINES 37

• OVERVIEW 56
• CURRENT VACCINES 56
• CSL BIOTHERAPIES 56
• GLAXOSMITHKLINE 57
• MEDIMMUNE 57
• NOVARTIS 57
• SANOFI PASTEUR 58
• SOLVAY PHARMACEUTICALS 58
• TABLE 18 MARKETED VACCINE PRODUCTS, THROUGH 2009 58
• SEASONAL 2008/2009 VACCINE APPROVALS 59
• TABLE 19 SEASONAL INFLUENZA VACCINE FDA APPROVALS FOR THE 2008 - 2009 INFLUENZA SEASON 59
• CURRENT THERAPIES 59
• TABLE 20 MARKETED THERAPIES, THROUGH 2009 60
• SEASONAL DOSAGE RECOMMENDATIONS FOR ANTIVIRALS 60
• TABLE 21 RECOMMENDED DAILY DOSAGE OF SEASONAL INFLUENZA ANTIVIRAL MEDICATIONS BY AGE: UNITED STATES 60
• TABLE 21 (CONTINUED) 61
• GENERIC AVAILABILITY 62
• TABLE 22 GENERIC FDA APPROVALS OF INFLUENZA APPROVED TREATMENTS 62
• VACCINE AND BIOLOGICAL DEVELOPMENTS 62
• ACAMBIS PLC 62
• ALNYLAM PHARMACEUTICALS 63
• ALPHAVAX 63
• BIOCRYST PHARMACEUTICALS 63
• BIONDVAX 63
• BIOTA HOLDINGS AND SANKYO COMPANY, LTD. 63
• CRUCELL 64
• CURELAB 64
• CYTOGENIX 64
• DYNAVAX TECHNOLOGIES 64
• GENEREX BIOTECHNOLOGY, 65
• GLAXOSMITHKLINE 65
• HEMISPHERX BIOPHARMA 65
• IMMUNEREGEN BIOSCIENCES, INC. 66
• INTERCELL 66
• MEDIMMUNE 66
• NANOVIRICIDES, INC. 66
• NEXBIO, INC. 67
• NOBILON 67
• NOVARTIS VACCINES 67
• NOVAVAX, INC. 67
• PROTEIN SCIENCES CORPORATION 68
• SANOFI PASTEUR 68
• SOLVAY PHARMACEUTICALS 68
• SINOVAC BIOTECH 69
• TOYAMA CHEMICAL 69
• VAXIN, INC.' S 69
• VAXINNATE 69
• VICAL, INC. 69
• TABLE 23 RESEARCH AND DEVELOPMENT EFFORTS BY PROGRESS 70
• TABLE 23 (CONTINUED) 71
• TABLE 23 (CONTINUED) 72
• CLINICAL TRIALS 72
• TABLE 24 CLINICAL TRIALS FOR INFLUENZA BY SELECTED COUNTRY AND TRIAL STATUS 73
• FIGURE 6 CLINICAL TRIALS FOR INFLUENZA BY SELECTED COUNTRY AND TRIAL STATUS 73
• RECENT INDUSTRY NEWS 74
• MARKET ANALYSIS 74
• TABLE 25 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY MARKET, THROUGH 2014 ($ MILLIONS) 75
• FIGURE 7 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY MARKET, 2007-2014 ($ MILLIONS) 75
• TABLE 26 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT TYPE, THROUGH 2014 ($ MILLIONS) 76
• FIGURE 8 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT TYPE, 2007-2014 ($ MILLIONS) 76
• THE GLOBAL INFLUENZA VACCINE MARKET 77
• TABLE 27 GLOBAL REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 77
• FIGURE 9 GLOBAL REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 78
• TABLE 28 UNITS FOR INFLUENZA VACCINES BY PRODUCT AND MANUFACTURER, 2005 - 2008 (MILLIONS) 79
• FIGURE 10 UNITS FOR INFLUENZA VACCINES BY MANUFACTURER, 2005 - 2006 SEASON (MILLIONS) 79
• FIGURE 11 UNITS FOR INFLUENZA VACCINES BY MANUFACTURER, 2006 - 2007 SEASON (MILLIONS) 80
• FIGURE 12 UNITS FOR INFLUENZA VACCINES BY MANUFACTURER, 2007 - 2008 SEASON (MILLIONS) 80
• The U.S. Influenza Vaccine Market 81
• TABLE 29 U.S. REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 82
• FIGURE 13 U.S. REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 82
• TABLE 30 ESTIMATED TOTAL UNITS SHIPPED TO THE UNITED STATES BY SEASON, 2005 - 2009 83
• FIGURE 14 ESTIMATED TOTAL UNITS SHIPPED TO THE UNITED STATES BY SEASON, 2005 - 2009 83
• TABLE 31 UNITS FOR INFLUENZA VACCINES DISTRIBUTED IN THE UNITED STATES BY MANUFACTURER, 2008 - 2009 (UNITS PER MILLION) 84
• FIGURE 15 SHARE OF UNITS FOR INFLUENZA VACCINES DISTRIBUTED IN THE UNITED STATES BY MANUFACTURER, 2008 - 2009 SEASON (%) 84
• The European Influenza Vaccine Market 84
• TABLE 32 EUROPE REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 85
• FIGURE 16 EUROPE REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 85
• THE GLOBAL INFLUENZA THERAPEUTICS MARKET 86
• TABLE 33 GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 86
• FIGURE 17 GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 87
• Influenza Therapeutics Market in the United States 87
• TABLE 34 U.S. REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 87
• FIGURE 18 U.S. REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 88
• Influenza Therapeutics Market in Europe 88
• TABLE 35 EUROPE REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 88
• FIGURE 19 EUROPE REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 89
• COMPETITOR ANALYSIS 89
• COMPETITOR ANALYSIS (CONTINUED) 90
• TABLE 36 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS/VACCINES BY PERCENT, BASED ON GLOBAL REVENUES, 2007 - 2009 (%) 91
• FIGURE 20 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS/VACCINES BY PERCENT, BASED ON GLOBAL REVENUES, 2007 (%) 91
• FIGURE 21 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS/VACCINES BY PERCENT, BASED ON GLOBAL REVENUES, 2008 (%) 92
• FIGURE 22 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS/VACCINES BY PERCENT, BASED ON GLOBAL REVENUES, 2009 (%) 92

Chapter-7: INFLUENZA DIAGNOSTICS 15

• OVERVIEW 93
• TABLE 37 INFLUENZA DIAGNOSTIC TABLE 93
• TABLE 37 (CONTINUED) 94
• PRODUCT DESCRIPTION 94
• Conventional Laboratory Tests 94
• Applied Biosystems 94
• Qiagen, Inc. 95
• TABLE 38 EXAMPLES OF CONVENTIONAL LABORATORY TESTS FOR INFLUENZA 95
• Rapid Testing 96
• 3M and Response Biomedical 96
• Becton Dickinson 96
• Diagnostic Hybrids 97
• Genzyme Diagnostics 97
• Inverness Laboratories 97
• Luminex 97
• Prodesse, Inc. 98
• Quidel 98
• Remel, Inc. 98
• SA Scientific, Ltd. 98
• TABLE 39 SELECTED MARKETED RAPID TEST PRODUCTS, THROUGH JUNE 2009 99
• TABLE 40 RAPID INFLUENZA TESTS AVERAGE PRICE ($) 100
• LABORATORY SERVICES 100
• Associated Regional University Pathologists (ARUP) Laboratories 100
• Bio - Reference Laboratories, Inc 100
• Laboratory Corporation of America 101
• Pathology Associates Medical Laboratories 101
• Quest Diagnostics 101
• Specialty Laboratories 102
• ViroMed Laboratories, Inc. 102
• TABLE 41 PROVIDERS OF TEST SERVICES 102
• INDUSTRY DEVELOPMENTS 102
• MARKET ANALYSIS 103
• TABLE 42 REVENUES FOR INFLUENZA DIAGNOSTICS BY MARKET, THROUGH 2014 ($ MILLIONS) 104
• FIGURE 23 REVENUES FOR INFLUENZA DIAGNOSTICS BY MARKET, 2007-2014 ($ MILLIONS) 104
• TABLE 43 REVENUES FOR INFLUENZA DIAGNOSTICS BY PRODUCT TYPE, THROUGH 2014 ($ MILLIONS) 105
• FIGURE 24 REVENUES FOR INFLUENZA DIAGNOSTICS BY PRODUCT TYPE, 2007-2014 ($ MILLIONS) 106
• MANUFACTURER REVENUES 106
• TABLE 44 GLOBAL REVENUES FOR INFLUENZA DIAGNOSTICS BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 107
• FIGURE 25 GLOBAL REVENUES FOR INFLUENZA DIAGNOSTICS BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 107

Chapter-8: MARKET SUMMARY 3

• TOTAL MARKET ANALYSIS 108
• TABLE 45 GLOBAL INFLUENZA MARKET ANALYSIS BY REVENUE SEGMENT, THROUGH 2014 ($ MILLIONS) 109
• FIGURE 26 GLOBAL INFLUENZA MARKET ANALYSIS, BY REVENUE SEGMENT, 2007-2014 ($ MILLIONS) 109
• INDUSTRY PARTICIPANTS 109
• TABLE 46 MAJOR INDUSTRY PARTICIPANTS BY PRODUCT SEGMENT, INDUSTRY PARTICIPANTS BY TYPE 110

Chapter-9: COMPANY PROFILES 17

• ASTRAZENECA/MEDIMMUNE 111
• TABLE 47 ASTRAZENECA' S COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 112
• FIGURE 27 ASTRAZENECA' S COMPANY REVENUES 2006 - 2009 ($ MILLIONS) 112
• BECTON DICKINSON 113
• TABLE 48 BECTON DICKINSON' S COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 113
• FIGURE 28 BECTON DICKINSON' S COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 114
• CSL BIOTHERAPIES 114
• TABLE 49 CSL LIMITED' S COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 115
• FIGURE 29 CSL LIMITED' S COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 115
• GLAXOSMITHKLINE 116
• TABLE 50 GLAXOSMITHKLINE' S COMPANY REVENUES 2006 - 2009 ($ MILLIONS) 117
• FIGURE 30 GLAXOSMITHKLINE' S COMPANY REVENUES 2006 - 2009 ($ MILLIONS) 117
• INVERNESS MEDICAL 117
• TABLE 51 INVERNESS MEDICAL' S COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 118
• FIGURE 31 INVERNESS MEDICAL' S COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 118
• NOVARTIS VACCINES AND DIAGNOSTICS 119
• TABLE 52 NOVARTIS' COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 120
• FIGURE 32 NOVARTIS' COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 120
• QUIDEL 121
• TABLE 53 QUIDEL' S COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 121
• FIGURE 33 QUIDEL' S COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 122
• ROCHE 122
• TABLE 54 ROCHE GROUP' S REVENUES, 2006 - 2009 ($ MILLIONS) 123
• FIGURE 34 ROCHE GROUP' S REVENUES, 2006 - 2009 ($ MILLIONS) 124
• SANOFI - AVENTIS/SANOFI PASTEUR 124
• SANOFI - AVENTIS/SANOFI PASTEUR (CONTINUED) 125
• TABLE 55 SANOFI - AVENTIS' COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 126
• FIGURE 35 SANOFI - AVENTIS' COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 126
• SOLVAY 126
• TABLE 56 SOLVAY' S COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 127
• FIGURE 36 SOLVAY' S COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 127

Chapter-10: APPENDIX 17

• APPENDIX 128
• MANUFACTURERS AND DEVELOPERS 128
• MANUFACTURERS AND DEVELOPERS (CONTINUED) 129
• MANUFACTURERS AND DEVELOPERS (CONTINUED) 130
• MANUFACTURERS AND DEVELOPERS (CONTINUED) 131
• MANUFACTURERS AND DEVELOPERS (CONTINUED) 132
• MANUFACTURERS AND DEVELOPERS (CONTINUED) 133
• MANUFACTURERS AND DEVELOPERS (CONTINUED) 134
• MANUFACTURERS AND DEVELOPERS (CONTINUED) 135
• MANUFACTURERS AND DEVELOPERS (CONTINUED) 136
• MANUFACTURERS AND DEVELOPERS (CONTINUED) 137
• MANUFACTURERS AND DEVELOPERS (CONTINUED) 138
• MANUFACTURERS AND DEVELOPERS (CONTINUED) 139
• MANUFACTURERS AND DEVELOPERS (CONTINUED) 140
• MENTIONED UNIVERSITIES 141
• RELEVANT ASSOCIATIONS AND ORGANIZATIONS 142
• RELEVANT ASSOCIATIONS AND ORGANIZATIONS (CONTINUED) 143
• RELEVANT ASSOCIATIONS AND ORGANIZATIONS (CONTINUED) 144